Association of humoral antitumor response with clinical benefit in catumaxomab-treated malignant ascites patients: Results from a phase IIIb study.

被引：0

作者：

Ruf, Peter

Suckstorff, Ivonne

Jaeger, Michael

Ernst, Christine

Seimetz, Diane

Lindhofer, Horst

机构：

[1] TRION Res GmbH, Martinsried, Germany

[2] Fresenius Biotech GmbH, Munich, Germany

[3] TRION Res GmbH, Munich, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2584

引用

页数：1

共 50 条

[31] Putative cancer stem cells (CD133+/EpCAM+) are eliminated from malignant ascites by the trifunctional antibody catumaxomab: results from a pivotal Phase II/III study
Lindhofer, H.
Schoberth, A.
Pelster, D.
Hess, J.
Herold, J.
Stroehlein, M.
Jaeger, M.
ONKOLOGIE, 2010, 33 : 157 - 157
[32] Maintenance of quality of life (QoL) and general health state in patients with malignant ascites during treatment with the trifunctional antibody catumaxomab: results from the phase III b CASIMAS trial
Lordick, F.
Sehouli, J.
Vergote, I
Rosenberg, P.
Schneeweiss, A.
Block, A.
Salat, C.
Scambia, G.
Berton-Rigaud, D.
Siena, S.
Santoro, A.
Cervantes-Ruiperez, A.
Guastalla, J. P.
Tournigand, C.
Colombo, N.
Dudnitchenko, A. S.
Bondar, V
Westermann, A. M.
Wimberger, P.
ONKOLOGIE, 2012, 35 : 62 - 63
[33] The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population)
Jaeger, M.
Schoberth, A.
Hennig, M.
Burges, A.
Heiss, M.
Wimberger, P.
Schmalfeldt, B.
Lindhofer, H.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[34] Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in ovarian cancer patients with malignant ascites
Jaeger, M. J.
Schoberth, A. M.
Heiss, M. M.
Lahr, A.
Lindhofer, H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[35] Durable clinical benefit is associated with objective response and not lack of progression in patients with relapsed/refractory chronic lymphocytic leukemia (CLL): Results from the Genasense/Flu/Cy phase 3 study.
Moore, Joseph O.
Boyd, Thomas E.
Chanan-Khan, Asher A.
O'Brien, Susan
BLOOD, 2006, 108 (11) : 800A - 800A
[36] Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.
Ba, Yi
Li, Jin
Qin, Shukui
Wen, Lu
Deng, Wenying
Zhang, Guifang
Jia, Tongfu
Zhong, Haijun
Yang, Jianwei
Lin, Xiaoyan
Bai, Yu-Xian
He, Yifu
Xie, Zhong
Yi, Tienan
Wu, Xiangyuan
Ye, Feng
Liu, Likun
Huang, Yong
Wang, Mei
Wang, Junsheng
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[37] Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab
Bingham, C. O., III
Rizzo, Warren C.
Klearman, Micki
Hassanali, Azra
Upmanyu, Ruchi
Kivitz, Alan J.
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S151 - S151
[38] Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study.
Jaeger, M
Stroehlein, MA
Schoberth, A
Burges, A
Heiss, MM
Lindhofer, H
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 164S - 164S
[39] EVALUATION OF TWO DOSING REGIMENS OF CERTOLIZUMAB PEGOL FOR MAINTENANCE OF CLINICAL RESPONSE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: PRIMARY RESULTS FROM DOSEFLEX, A PHASE IIIB STUDY
Furst, D. E.
Shaikh, S. A.
Greenwald, M.
Bennett, B.
Staelens, F.
Koetse, W.
Bertin, P.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 513 - 513
[40] Histological analysis in pemetrexed treated patients with stage IIIB/IV NSCLC: results from an open label randomized phase II study
Niho, Seiji
Kubota, Kaoru
Enatsu, Sotaro
Nambu, Yoshihiro
Nishiwaki, Yutaka
Saijo, Nagahiro
Fukuoka, Masahiro
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S533 - S533

← 1 2 3 4 5 →